Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.

Benjamin J Samelson-Jones Christine J Guelcher Janice KuhnRegina ButlerGita MasseyMichael F GuerreraLeslie Raffini

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

Starting or switching to prophylaxis with emicizumab results in decreased costs for the treatment of patients with haemophilia A. This real-world data could inform on payer decisions as well as future cost-effective analysis.

Keyphrases

electronic health record
current status
big data
combination therapy
replacement therapy
deep learning